				4 .	L	-		Shee	元 红 of 1	-
	APPLICAN REV 7-80	T FACSIMIL	E OF FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE CITED BY APPLICANT ets if necessary)		JAG-004		SERIAL NO. 09/587,662	EED F	1
OIPI	VC/63	ST OF	PUBLICATIONS (Use several shee			Au, Jessie LS. et al. Filing Date		GROUP	0 3 200 ITER 1600	•
INT O	ղ <u>իզու բ</u> Հ			U.S. PATENT DOC		June 5, 2000		1020	0) 0/290(
PIENT & TH	OE NER		DOCUMENT NUMBER	DATE	NAME '		CLASS	SUBCLASS	FILING D	DATE
	an	A1	5,645,986	07/97	West et al.		435	6		
	CHA	A2	5,972,605	10/99	Villeponteau		435	6		
	UXI) A3	6,007,989	12/99	West et al.		435	6		
) A4	6,022,709	02/00	de Lange et al.		435	69.1		
	Cy	A5	6,046,307	04/00	Shay et al.		530	324		
						*				
				FOR	EIGN PATENT DO	OGUMENTS				-
			DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS	TRAŃSL	ATION NO
	an	A6	WO 96/01835	01/96	PCT					
	64	A7	WO 96/19580	06/96	PCT			<u> </u>		
	4	A8	WO 96/41016	12/96	PCT					
	6/1	A9	WO 97/38013	10/97	PCT		—			
	Con	A10	WO 98/14593	04/98	PCT					
	CA.	A11	WO 98/21343	05/98	PCT					
	an	A12	WO 99/09212	02/99	PCT					
	77								T	
OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)										
	Gschwentner, M. et al., "Antiviral drugs from the nucleoside analog family block volume-activated chloride channels," <i>Mol. Med.</i> 1(4):407-17 (1995)									
	Huminiecki, L. "Telomerase as a therapeutic target," <i>Acta Biochimica Polonica</i> , 43(3):531-8 (1996)									
		A15	Kondo, Y. et al., "Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis," <i>Oncogene</i> 16(17):2243-8 (1998) Neidle, S. et al., "Commentary: Telomerase as an anti-cancer target: current status and future prospects," <i>Anti Cancer Drug Design</i> , 14:341-347 (1999) Rha, S. Y. et al., "Effect of telomere and telomerase interactive agents on human tumor and normal cell lines," <i>Clin. Cancer Res.</i> 6(3):987-93 (2000)							
	M	A16								
	BA	A17								
	183	A18	Viora, M. et al.	., "Interfere	ence with cell cycle	e progression and in opharmacol. 19(6):			рy	
	1 7/1 1	-+			`			•		

EXAMPLER:

Date Considered

12/17/2002

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.